News

Published on 24 Jan 2024 on GuruFocus.com via Yahoo Finance

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares

Article preview image

David Jones, SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 35,066 shares in the company on January 23, 2024, according to a recent SEC filing.

Warning! GuruFocus has detected 4 Warning Signs with EYPT.

EyePoint Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of treatments for ocular diseases. The company's portfolio includes therapies for conditions such as uveitis, diabetic macular edema, and other eye-related diseases.

Read the rest of the article
NASDAQ.EYPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge - Spirit Airlines (NYSE:SAVE)

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 1...

Benzinga 6 May 2024
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com

EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...

Investing.com 6 May 2024
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving...

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of S...

Benzinga 6 May 2024
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's...

Shares of Perficient, Inc PRFT shares rose sharply during Monday's session after the company disc...

Benzinga 6 May 2024
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? On Monday, EyePoint Pharmaceuticals I...

Benzinga via Yahoo Finance 6 May 2024
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal

dropped nearly 30% in premarket trading Monday after the company said its experimental...

Market Watch 6 May 2024
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)

EyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Pha...

Seeking Alpha 6 May 2024
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.46%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.46%

Investing.com 6 May 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By...

One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - they ...

Simply Wall St. via Yahoo Finance 9 Mar 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePo...

Insider Monkey via Yahoo Finance 8 Mar 2024

Copyright Statfolio @ 2024

Social Accounts